"Neoplasm Invasiveness" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
| Descriptor ID |
D009361
|
| MeSH Number(s) |
C04.697.645 C23.550.727.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Invasiveness".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Invasiveness".
This graph shows the total number of publications written about "Neoplasm Invasiveness" by people in this website by year, and whether "Neoplasm Invasiveness" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 4 | 4 |
| 2011 | 1 | 9 | 10 |
| 2012 | 0 | 10 | 10 |
| 2013 | 1 | 9 | 10 |
| 2014 | 0 | 12 | 12 |
| 2015 | 1 | 9 | 10 |
| 2016 | 1 | 9 | 10 |
| 2017 | 0 | 10 | 10 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 10 | 10 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Invasiveness" by people in Profiles.
-
CHD4 drives gastric cancer metastasis via MYH9/GSK3?/?-catenin axis and WNT/EMT pathway activation. Cancer Lett. 2025 Sep 28; 628:217813.
-
Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: A retrospective cohort study. J Am Acad Dermatol. 2025 Jul; 93(1):157-164.
-
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Gu?rin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review. Clin Genitourin Cancer. 2025 Jun; 23(3):102313.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
-
Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
-
Interlobular Septal Thickening in a Young Man With Dyspnea. Chest. 2021 12; 160(6):e645-e650.
-
Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2021 09 21; 2(9):100399.
-
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
-
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.